Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

 March 26, 2026

BioPharma Dive

Wave s drug, which is meant to improve body composition, disappointed investors but was defended by analysts.

Clinical DataMetabolic & GLP-1Read full story

Post navigation

Maze tumbles despite positive data for kidney disease drug →
← FDA clears Denali drug in ‘clear step’ for rare disease biotechs

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com